Neoplasia — MCQs

Q: What is the most common site for salivary gland tumors?

Parotid salivary gland. **Explanation:** The distribution of salivary gland tumors follows a specific rule of thumb: the larger the gland, the more likely it is to develop a tumor, but the less likely that tumor is to be malignant. 1. **Parotid Gland (Correct):** Approximately **65% to 80%** of all salivary gland tumors arise in the parotid gland [1]. While it is the most common site for neoplasia, the majority (about 75–80%) of these tumors are benign, with **Pleomorphic Adenoma** being the most frequent histological type [1]. 2. **Submandibular Gland (Incorrect):** This is the second most common site, accounting for roughly 10% of tumors [1]. Unlike the parotid, about 40% of tumors here are malignant. 3. **Sublingual Gland (Incorrect):** Tumors in this gland are rare (less than 1%). However, there is a high clinical suspicion of malignancy; approximately 70–90% of sublingual tumors are malignant. 4. **Submaxillary Gland (Incorrect):** This is simply another name for the submandibular gland. **NEET-PG High-Yield Pearls:** * **Most common benign tumor (all glands):** Pleomorphic Adenoma (Mixed tumor) [1]. * **Most common malignant tumor (all glands):** Mucoepidermoid Carcinoma [1]. * **Warthin’s Tumor (Papillary Cystadenoma Lymphomatosum):** Almost exclusively found in the parotid gland; strongly associated with smoking and often bilateral [1]. * **Adenoid Cystic Carcinoma:** Most common malignant tumor of the submandibular and minor salivary glands; known for **perineural invasion** [1]. * **Rule of Proportion:** As the size of the gland decreases, the risk of malignancy increases. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Head and Neck, pp. 750-755.

Neoplasia Indian Medical PG Practice Questions and MCQs

Question 1: What is the most common carcinoma to develop after burns?

A. Squamous cell carcinoma (Correct Answer)
B. Adenocarcinoma
C. Melanoma
D. Mucoid carcinoma

Explanation: **Explanation:** The correct answer is **Squamous Cell Carcinoma (SCC)**. This specific clinical scenario refers to a **Marjolin’s ulcer**, which is a malignancy arising in a chronic non-healing wound, scar tissue, or most classically, a **long-standing burn scar** [1]. **Why it is correct:** Chronic irritation, persistent inflammation, and repeated trauma to a burn scar lead to constant cellular turnover. Over time, the damaged skin undergoes malignant transformation. In the skin, the predominant cell type is the keratinocyte; therefore, the resulting malignancy is almost always Squamous Cell Carcinoma [1]. Marjolin’s ulcers are typically more aggressive and have a higher rate of metastasis than SCC arising from sun-damaged skin. **Why other options are incorrect:** * **B. Adenocarcinoma:** This arises from glandular epithelium (e.g., GI tract, breast, lung). Skin lacks the primary glandular structures required for this to be a common post-burn complication. * **C. Melanoma:** While melanoma arises from melanocytes in the skin, it is associated with UV radiation and genetic factors rather than chronic scarring or thermal injury. * **D. Mucoid carcinoma:** This is a variant of adenocarcinoma (often seen in the breast or GI tract) characterized by abundant mucin production; it has no association with burn scars. **High-Yield Pearls for NEET-PG:** * **Marjolin’s Ulcer:** The classic triad is a chronic scar, a non-healing ulcer, and Squamous Cell Carcinoma [1]. * **Latent Period:** The average time from the initial burn to the development of SCC is often **20–30 years**. * **Other associations:** Marjolin’s ulcers can also develop in chronic osteomyelitis sinuses and venous stasis ulcers [1]. * **Diagnosis:** Always perform a biopsy on any ulcerating lesion appearing in an old scar. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Disorders Involving Inflammatory And Haemopoietic Cells, pp. 644-645.

Question 2: A female patient presents with a 2 x 2 cm firm mass in the upper outer quadrant of the breast. She has a family history of ovarian carcinoma. Which investigation needs to be done to assess for a specific gene mutation?

A. p53
B. BRCA-2 (Correct Answer)
C. Her 2/Neu gene
D. C-myc gene

Explanation: ### Explanation **Correct Option: B (BRCA-2)** The clinical presentation of a breast mass in a patient with a strong family history of ovarian carcinoma strongly suggests **Hereditary Breast and Ovarian Cancer (HBOC) syndrome**. [1] * **BRCA-1 and BRCA-2** are tumor suppressor genes involved in DNA repair (homologous recombination). [1] * While both increase the risk of breast and ovarian cancer, **BRCA-2** is specifically associated with a higher risk of male breast cancer and is frequently tested when there is a strong clustering of these two specific malignancies in a family. In the context of this question, it is the most specific marker for the dual risk of breast and ovarian carcinoma. **Why other options are incorrect:** * **A. p53:** Mutations in p53 are associated with **Li-Fraumeni Syndrome**. While this increases breast cancer risk, it typically presents with a broader spectrum of tumors (Sarcomas, Brain tumors, Leukemia, and Adrenocortical carcinoma) rather than a specific breast-ovarian link. [2] * **C. Her 2/Neu:** This is a proto-oncogene (ERBB2). Testing is done for **prognosis and treatment stratification** (Trastuzumab therapy) in confirmed cases, but it is a somatic mutation, not a germline mutation used to assess familial predisposition. [2] * **D. C-myc:** This oncogene is primarily associated with **Burkitt Lymphoma** (t(8;14)). It does not have a primary diagnostic role in familial breast-ovarian cancer syndromes. **High-Yield Clinical Pearls for NEET-PG:** * **BRCA-1 Location:** Chromosome 17q21. * **BRCA-2 Location:** Chromosome 13q12.3. * **Most common breast cancer type in BRCA-1:** Triple Negative (Basal-like). * **Most common breast cancer type in BRCA-2:** ER positive (Luminal). [2] * **Other BRCA-2 associations:** Prostate, Pancreatic, and Gallbladder cancer. [1] **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1058-1059. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1059-1060.

Question 3: Which of the following conditions is not considered a premalignant condition?

A. Erosive lichen planus
B. Syphilitic glossitis
C. Leukoedema (Correct Answer)
D. Leukoplakia

Explanation: **Explanation:** The core concept in this question is distinguishing between **potentially malignant disorders (PMDs)** and **normal anatomical variations** of the oral mucosa. **Why Leukoedema is the correct answer:** Leukoedema is a **benign, physiological variation** of the oral mucosa, not a premalignant condition. It is characterized by a diffuse, greyish-white, milky opalescence of the buccal mucosa that **disappears when the tissue is stretched** (a key diagnostic feature). Histologically, it shows intracellular edema of the spinous layer but lacks cellular atypia or dysplasia. It has no potential for malignant transformation. **Analysis of Incorrect Options:** * **Erosive Lichen Planus:** While the reticular form has a very low risk, the **erosive and atrophic forms** of Oral Lichen Planus are recognized as premalignant conditions with a transformation rate of approximately 1-2%. * **Syphilitic Glossitis:** Chronic interstitial glossitis in tertiary syphilis is a classic premalignant condition. The associated atrophy and chronic inflammation of the tongue dorsum significantly increase the risk of squamous cell carcinoma. * **Leukoplakia:** This is the **most common** premalignant lesion of the oral cavity [1]. It is a clinical term for a white patch that cannot be rubbed off or characterized as any other disease [1]. The risk of malignancy depends on the degree of dysplasia. **High-Yield Clinical Pearls for NEET-PG:** * **Leukoedema:** Most common in African Americans and smokers; "disappears on stretching" is the pathognomonic clinical sign. * **Highest Malignant Potential:** Among oral lesions, **Erythroplakia** (red patch) has a much higher risk of malignancy (up to 90% show dysplasia/carcinoma) compared to Leukoplakia. * **Speckled Leukoplakia:** Also known as Erythroleukoplakia, it carries a higher risk than homogenous leukoplakia. * **Other PMDs:** Oral Submucous Fibrosis (OSMF) and Sideropenic Dysphagia (Plummer-Vinson Syndrome) are other high-yield premalignant conditions. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Alimentary System Disease, pp. 344-345.

Question 4: A 55-year-old female presents with swollen, red, and tender right breast. The physician palpates a firm area and suspects inflammatory breast cancer. Which of the following best describes the histological changes observed in this disorder?

A. Acute inflammation in breast carcinoma
B. Chronic inflammation in breast carcinoma
C. Dermal lymphatic invasion by cancer cells (Correct Answer)
D. Epidermal invasion by cancer cells

Explanation: ### Explanation **1. Why the Correct Answer is Right:** The clinical presentation of a swollen, red, and tender breast (mimicking mastitis) in an older female is a classic description of **Inflammatory Breast Cancer (IBC)**. Despite the name, the "inflammatory" appearance is not due to an underlying infection or leukocyte infiltration. Instead, it is caused by **tumor emboli obstructing the dermal lymphatic channels**. This obstruction leads to lymphatic congestion and lymphedema, which manifests clinically as the characteristic **"Peau d'orange"** (orange peel) appearance of the skin [1]. **2. Why the Incorrect Options are Wrong:** * **Options A & B:** While the breast appears clinically inflamed (rubor, tumor, calor), the underlying pathology is **not** an infiltration of acute (neutrophils) or chronic (lymphocytes/plasma cells) inflammatory cells. It is a mechanical blockage of lymphatics by malignant cells. * **Option D:** Epidermal invasion by cancer cells is characteristic of **Paget’s Disease of the Breast**, where malignant cells (Paget cells) migrate from an underlying ductal carcinoma in situ (DCIS) into the nipple epidermis, causing an eczematous, crusting lesion. **3. High-Yield Clinical Pearls for NEET-PG:** * **Clinical Diagnosis:** IBC is a clinical-pathologic diagnosis. If a patient suspected of having mastitis does not respond to a course of antibiotics, a biopsy is mandatory to rule out IBC. * **Prognosis:** IBC is highly aggressive (T4d in TNM staging) and is considered Stage IIIB or IV at the time of diagnosis. * **Peau d'orange:** This occurs because the skin is tethered by the suspensory ligaments of Cooper, while the intervening skin is swollen due to lymphatic edema [1]. * **Molecular Profile:** IBC is frequently ER/PR negative and often shows HER2/neu overexpression. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 453-454.

Question 5: Which mutation is seen in malignant melanoma?

A. N-MYC
B. RB gene
C. CDKN2A (Correct Answer)
D. p53

Explanation: **Explanation:** **CDKN2A** (located on chromosome 9p21) is the most frequently mutated gene in both familial and sporadic **Malignant Melanoma** [3]. It is a complex locus that encodes two critical tumor suppressor proteins: **p16/INK4a** (which inhibits CDK4/6, maintaining the RB pathway) and **p14/ARF** (which prevents p53 degradation) [1]. Mutations in CDKN2A lead to uncontrolled cell cycle progression through the G1-S checkpoint [4]. **Analysis of Incorrect Options:** * **A. N-MYC:** This oncogene is characteristically amplified in **Neuroblastoma** and is a significant prognostic marker (indicates poor prognosis). * **B. RB Gene:** Located on chromosome 13q14, mutations in the Retinoblastoma (RB) gene are primarily associated with **Retinoblastoma** and **Osteosarcoma**. While the RB *pathway* is affected in melanoma via p16 loss, the primary mutation is in CDKN2A [3]. * **D. p53:** Known as the "Guardian of the Genome," it is the most common mutation in human cancers overall. However, in the specific context of melanoma, CDKN2A and BRAF mutations are more characteristic and diagnostic hallmarks [1]. **High-Yield Clinical Pearls for NEET-PG:** * **BRAF Mutation:** The most common somatic mutation in sporadic melanoma (specifically **V600E**). It involves the MAPK signaling pathway [1]. * **KIT Mutation:** Commonly seen in mucosal and acral lentiginous melanomas [1]. * **Breslow’s Depth:** The most important prognostic factor for melanoma (measures vertical thickness) [2]. * **S-100 & HMB-45:** Key immunohistochemical (IHC) markers for diagnosis. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1150-1151. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1152-1153. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 305-306. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 297-298.

Question 6: Which of the following is a marker of Paget's disease of the mammary gland?

A. CEA (Correct Answer)
B. S-100
C. HMB-45
D. Neuron-specific enolase

Explanation: **Explanation:** **Paget’s disease of the breast** is a condition where malignant glandular cells (Paget cells) infiltrate the squamous epithelium of the nipple-areola complex [1]. These cells originate from an underlying ductal carcinoma (either DCIS or invasive carcinoma) [1], [2]. **Why CEA is the correct answer:** Paget cells are **adenocarcinoma** cells. Therefore, they express epithelial and glandular markers. **Carcinoembryonic Antigen (CEA)** is a well-known oncofetal antigen expressed by glandular tumors. Other characteristic markers for Paget’s disease include **Mucicarmine** (staining intracellular mucin), **Low Molecular Weight Keratin (LMWK)**, and **HER2/neu** (overexpressed in ~90% of cases) [1]. **Analysis of Incorrect Options:** * **B. S-100:** This is a marker for cells of neural crest origin (melanocytes, Schwann cells) and chondrocytes. While it can be positive in Melanoma, it is typically negative in Paget’s disease. * **C. HMB-45:** This is a highly specific marker for **Melanoma**. Since Paget’s disease clinically mimics Malignant Melanoma of the nipple, HMB-45 is used to differentiate the two; it will be negative in Paget’s and positive in Melanoma. * **D. Neuron-specific enolase (NSE):** This is a marker for **neuroendocrine tumors** (like Small Cell Carcinoma or Carcinoid) and neural tumors, which is not the lineage of Paget cells. **NEET-PG High-Yield Pearls:** * **Clinical Presentation:** Chronic eczematous crusting of the nipple that does *not* heal with topical steroids. * **Pathology:** Large, pale cells with "halos" (clear cytoplasm) located within the epidermis [1], [2]. * **Key Differentiator:** Paget cells are **PAS positive** (diastase resistant) due to mucin content, whereas Melanoma cells are PAS negative. * **Associated Finding:** Almost always associated with an underlying malignancy (DCIS or Invasive Ductal Carcinoma) [1], [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1061-1062. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 456-457.

Question 7: Which of the following is NOT a condition associated with tumor suppressor gene dysfunction?

A. Breast cancers
B. Neurofibromatosis
C. Multiple endocrine neoplasia (Correct Answer)
D. Retinoblastoma

Explanation: **Explanation:** The core concept tested here is the classification of genes involved in oncogenesis. **Tumor Suppressor Genes (TSGs)** act as "brakes" on cell proliferation; their loss of function leads to cancer [4]. In contrast, **Proto-oncogenes** promote cell growth; their gain of function (activation) leads to cancer [4]. **Why Option C is Correct:** **Multiple Endocrine Neoplasia (MEN)** syndromes are primarily associated with **proto-oncogene** mutations or specific gene activations rather than classic TSG dysfunction. * **MEN 2A and 2B** are caused by a gain-of-function mutation in the **RET proto-oncogene**. * While MEN 1 involves the *MEN1* gene (which is a TSG) [1], the presence of the RET proto-oncogene in the MEN spectrum makes it the "odd one out" when compared to the other options which are classic, pure examples of the "Two-Hit Hypothesis" of TSGs [3]. **Why Other Options are Incorrect:** * **Retinoblastoma (Option D):** The prototype of TSG dysfunction. It involves the **RB1 gene**. It follows Knudson’s two-hit hypothesis [2]. * **Neurofibromatosis (Option B):** Caused by mutations in **NF1** (Neurofibromin) or **NF2** (Merlin), both of which are classic tumor suppressor genes. * **Breast Cancers (Option A):** Frequently associated with mutations in **BRCA1 and BRCA2**, which are TSGs involved in DNA repair [2]. **High-Yield Clinical Pearls for NEET-PG:** 1. **RET Proto-oncogene:** Associated with MEN 2A, 2B, and Medullary Thyroid Carcinoma. 2. **Two-Hit Hypothesis:** Applies to TSGs (like *RB*, *TP53*, *APC*), where both alleles must be inactivated to trigger oncogenesis [3]. 3. **Gatekeepers vs. Caretakers:** TSGs like *RB* are "Gatekeepers" (control cell cycle), while *BRCA1/2* are "Caretakers" (maintain genomic stability) [2]. 4. **TP53:** The "Guardian of the Genome," the most commonly mutated TSG in human cancers [4]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1139-1140. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 300. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 298-300. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 297-298.

Question 8: What is the most common site for salivary gland tumors?

A. Parotid salivary gland (Correct Answer)
B. Submandibular salivary gland
C. Sublingual gland
D. Submaxillary gland

Explanation: **Explanation:** The distribution of salivary gland tumors follows a specific rule of thumb: the larger the gland, the more likely it is to develop a tumor, but the less likely that tumor is to be malignant. 1. **Parotid Gland (Correct):** Approximately **65% to 80%** of all salivary gland tumors arise in the parotid gland [1]. While it is the most common site for neoplasia, the majority (about 75–80%) of these tumors are benign, with **Pleomorphic Adenoma** being the most frequent histological type [1]. 2. **Submandibular Gland (Incorrect):** This is the second most common site, accounting for roughly 10% of tumors [1]. Unlike the parotid, about 40% of tumors here are malignant. 3. **Sublingual Gland (Incorrect):** Tumors in this gland are rare (less than 1%). However, there is a high clinical suspicion of malignancy; approximately 70–90% of sublingual tumors are malignant. 4. **Submaxillary Gland (Incorrect):** This is simply another name for the submandibular gland. **NEET-PG High-Yield Pearls:** * **Most common benign tumor (all glands):** Pleomorphic Adenoma (Mixed tumor) [1]. * **Most common malignant tumor (all glands):** Mucoepidermoid Carcinoma [1]. * **Warthin’s Tumor (Papillary Cystadenoma Lymphomatosum):** Almost exclusively found in the parotid gland; strongly associated with smoking and often bilateral [1]. * **Adenoid Cystic Carcinoma:** Most common malignant tumor of the submandibular and minor salivary glands; known for **perineural invasion** [1]. * **Rule of Proportion:** As the size of the gland decreases, the risk of malignancy increases. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Head and Neck, pp. 750-755.

Question 9: Which of the following statements is false regarding the role of HPV in oncogenesis?

A. Expresses oncogenic proteins
B. Inactivates tumor suppressors
C. Inactivates cyclins (Correct Answer)
D. Inhibits apoptosis

Explanation: **Explanation:** The oncogenic potential of High-Risk Human Papillomavirus (HPV), particularly types 16 and 18, is primarily mediated by its early genes, **E6 and E7** [1]. **Why "Inactivates cyclins" is False (Correct Answer):** HPV does not inactivate cyclins; in fact, it **activates** them [1]. Specifically, the E7 protein binds to the Retinoblastoma (Rb) protein, displacing the E2F transcription factor. This leads to the increased expression of **Cyclin E and Cyclin A**, which drives the cell cycle from the G1 to the S phase [1], [3]. Therefore, HPV promotes cyclin activity rather than inhibiting it. **Why the other options are True:** * **Expresses oncogenic proteins:** HPV expresses E6 and E7, which are classic viral oncoproteins essential for malignant transformation [1]. * **Inactivates tumor suppressors:** This is the hallmark of HPV pathogenesis. **E6** binds to and facilitates the degradation of **p53** (via ubiquitin ligase E6AP), while **E7** binds and inactivates **pRb** [1], [4]. * **Inhibits apoptosis:** By degrading p53, the E6 protein prevents p53-mediated apoptosis in response to DNA damage, allowing mutated cells to survive and proliferate [1]. **High-Yield Clinical Pearls for NEET-PG:** * **E6 = p53** (Mnemonic: Six rhymes with P-fiv-ty-Six/p53). * **E7 = Rb** (Mnemonic: 7 looks like a 'b' or 'E7-Rb'). * **p16INK4a:** Inactivation of Rb by E7 leads to a compensatory **overexpression of p16**, which serves as a reliable immunohistochemical (IHC) marker for HPV-related cervical intraepithelial neoplasia (CIN) [2]. * **Integration:** Malignant transformation occurs when the circular HPV genome integrates into the host DNA, typically resulting in the loss of the **E2 repressor gene**, which leads to the uncontrolled overexpression of E6 and E7. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 334-335. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1007-1008. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 300-301. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 301-302.

Question 10: All of the following are tumor markers, except?

A. CEA
B. HCG
C. Alpha-fetoprotein
D. Beta-2 macroglobulin (Correct Answer)

Explanation: ### Explanation The correct answer is **D. Beta-2 macroglobulin**. In medical oncology, tumor markers are substances (proteins, enzymes, or hormones) produced by cancer cells or by the body in response to cancer [2]. While **Beta-2 microglobulin (B2M)** is a well-known tumor marker used in multiple myeloma and lymphomas, **Beta-2 macroglobulin** is not a recognized tumor marker. This is a classic "distractor" question testing your precision with medical terminology. #### Analysis of Options: * **CEA (Carcinoembryonic Antigen):** An oncofetal antigen primarily used to monitor recurrence in **colorectal carcinoma**. It can also be elevated in pancreatic, gastric, and breast cancers [2], [4]. * **HCG (Human Chorionic Gonadotropin):** A hormone marker secreted by trophoblastic cells. It is the primary marker for **Choriocarcinoma** and **Hydatidiform mole**, and is also elevated in certain germ cell tumors (e.g., Seminoma) [1]. * **Alpha-fetoprotein (AFP):** An oncofetal protein used in the diagnosis and monitoring of **Hepatocellular Carcinoma (HCC)** and **Yolk sac tumors** (Endodermal sinus tumors) [2], [3]. * **Beta-2 macroglobulin:** This is the incorrect term. The actual marker is **Beta-2 microglobulin**, which forms the light chain of the MHC Class I molecule. #### High-Yield Clinical Pearls for NEET-PG: * **Most specific marker for Prostate Cancer:** PSA (Prostate-Specific Antigen) [2]. * **CA-125:** Associated with Ovarian Cancer (Surface epithelial tumors). * **CA 19-9:** Associated with Pancreatic and Cholangiocarcinoma. * **Calcitonin:** Marker for Medullary Carcinoma of the Thyroid. * **Note:** Most tumor markers are used for **monitoring response to therapy** and detecting recurrence, rather than primary diagnosis [2], [3] (except for a few like AFP in high-risk patients or PSA). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 512-513. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 346. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 254-255. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 319-320.

Practice by Chapter

Nomenclature and Classification of Tumors

Practice Questions

Characteristics of Benign and Malignant Neoplasms

Practice Questions

Molecular Basis of Cancer

Practice Questions

Carcinogenesis and Carcinogens

Practice Questions

Tumor Progression and Metastasis

Practice Questions

Tumor Markers

Practice Questions

Paraneoplastic Syndromes

Practice Questions

Genetic Basis of Cancer

Practice Questions

Tumor Immunity

Practice Questions

Cancer Epidemiology and Prevention

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Neoplasia — MCQs

Neoplasia — MCQs

On this page

Practice by Chapter

Want unlimited practice?